

Martin Jönsson  
CEO

May 11, 2021  
Company Overview & Goals



# AlzeCure Pharma

- Founded in **2016**, out of a research foundation sponsored by Alzheimerfonden
- **Experienced team** with extensive background within Pharma industry
- Based at Novum Science Park, **Karolinska Institute**, Stockholm, Sweden
- Working in **Alzheimer's Disease (AD)** and **Pain** – multi-billion markets / great unmet medical need
- Three project platforms with multiple candidates
  - **NeuroRestore®** - A novel first-in-class symptomatic treatment for cognitive disorders, e.g. AD
  - **Alzstatin®** – An innovative disease-modifying treatment for AD
  - **Painless** – Innovative projects for osteoarthritic and neuropathic pain
- Listed on **Nasdaq's First North Premier Growth Market** since Nov. 2018 (Ticker: ALZCUR)
- Market cap: **SEK 261m** (May 10, 2021)
- Cash position: **SEK 94m** (Q1 2021 report)



# Our Business Model

- We are a **Research & Development** company
- Research & **develop to early clinical phase** and then **out-license** our projects
- Gain incomes through:
  - **Upfront payments,**
  - **Milestone payments** and
  - **Royalties** on sold products





# Our primary Focus area

## Alzheimer's Disease


- Costs the society more than **oncology and cardiovascular diseases** TOGETHER
- The patient population and costs will **TRIPLE** in the next 30 years



# Two Alzheimer's platforms - 1st-in-class properties & potential game- changers

TARGET TWO KEY AREAS WITH A HIGH UNMET MEDICAL NEED

Disease-modifying therapy



**Alzstatin®**

*Targeting Amyloid Production*  
- Novel Oral Small Molecule

Symptomatic therapy



**NeuroRestore®**

*Improving Neuronal Function*  
- Novel Oral Small Molecule

# Our second Focus area

## Pain

- Suicide due to chronic pain is as common as due to depression
- Most common cause for sick leaves, creating high societal costs
- Opioid crisis in the US is huge – reversing the mean average lifespan of Americans



**Huge need** for more efficacious and safer treatments

# Our platform PAINLESS – Targeting unmet medical needs within pain



## Neuropathic pain\*

25 – 30 million patients

Project: ACD440



## Osteoarthritis & severe pain conditions

250 – 300 million patients

Project: TrkA-NAM

# A pipeline of small-molecule programs

– Multiple candidates increase chance of success

Platform	Candidate	Indication	Research phase	Preclinical phase	Phase I	Phase II	Phase III
NeuroRestore®	ACD856	Alzheimer's Disease, Sleep disorders, Traumatic brain injuries Parkinson's disease				Ongoing <b>Fully funded Ph I study</b>	
	ACD857	Alzheimer's Disease					
Alzstatin®	ACD679	Alzheimer's Disease					
	ACD680	Alzheimer's Disease					
Painless	ACD440	Neuropathic Pain				Recently ended <b>Fully funded Ph Ib study</b>	
	TrkA-NAM	Osteoarthritic Pain & other severe pain conditions					

Phase completed

Phase ongoing





## Key short-term milestones for 2021

- ☒ **Read-out** of clinical 1b study **Painless ACD440** in summer 2021
- ☐ **Read-out** of clinical 1a SAD study **NeuroRestore<sup>®</sup> ACD856** summer 2021
- ☐ **Start NeuroRestore<sup>®</sup> ACD856** 1a MAD clinical study in second half 2021
- ☐ **Select CD** for our pain project **TrkA-NAM** in second half 2021
- ☐ **File for 2a clinical study for Painless ACD440** in neuropathic pain second half 2021



Karolinska Institutet Novum Science Park  
Hälsövägen 7, 141 57 Huddinge, Stockholm  
[www.alzecurepharma.se](http://www.alzecurepharma.se)